ArticleNature communications2026
An in vitro approach for simulating divergent Golgi O-glycosylation of tumor-associated MUC1 from normal MUC1.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide O-glycosylation relies on the coordinated action of glycosyltransferases across the endoplasmic reticulum (ER) and Golgi apparatus. However, the molecular mechanisms driving aberrant glycosylation in cancer remain poorly understood. Here we show an in vitro one-pot synthetic biology approach that simulates divergent glycosylation pathways to map the synthesis of mucin 1 (MUC1) tumor-associated antigens. By modeling the cancer-associated relocation of initiation enzymes (GALNTs) to the ER, we demonstrate that this spatial shift leads to complete GalNAc (Tn antigen) occupancy. This occurs because ER localization extends reaction times and prevents inhibition by downstream Golgi enzymes. Furthermore, combined kinetic and computer reaction dynamic simulations reveal that ST6GALNAC1 exclusively drives α-2-6 sialylation, with a strict preference for the T13 site on fully glycosylated MUC1. This suggests that cancer-associated sTn upregulation is directly linked to T13 occupancy. Ultimately, this systems modeling approach decodes the enzyme localization and substrate specificities fundamental to tumourigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.